Evidence map›Paper›PMID 20202993›Full record

ArticleToxicological sciences : an official journal of the Society of Toxicology2010

Integration of mutation and chromosomal damage endpoints into 28-day repeat dose toxicology studies.

Stephen D Dertinger, Souk Phonethepswath, Dean Franklin, Pamela Weller, Dorothea K Torous, Steven M Bryce, Svetlana Avlasevich, Jeffrey C Bemis, Ollivier Hyrien, James Palis and 1 more

Open access · bronzeAbstract read
In one paragraph

Article in Toxicological sciences : an official journal of the Society of Toxicology, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.

0numbers the graph read from it
0cells of the map it votes in
18citing papers in PubMed
3.7field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

18 citing papers in PubMed, 91 citations in OpenAlex.

  1. Erythrocyte-Based Pig-a Gene Mutation Assay.Methods in molecular biology (Clifton, N.J.) · 2026
    Article
  2. Review
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Predicting the future: opportunities and challenges for the chemical industry to apply 21st-century toxicity testing.Journal of the American Association for Laboratory Animal Science : JAALAS · 2015
    Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. How accurate is in vitro prediction of carcinogenicity?British journal of pharmacology · 2011
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 3 institutions in 1 country.

Stephen D DertingerLitron Laboratories, Rochester, New York 14623, USA. sdertinger@litronlabs.com
Souk Phonethepswath
Dean Franklin
Pamela Weller
Dorothea K Torous
Steven M Bryce
Svetlana Avlasevich
Jeffrey C Bemis
Ollivier Hyrien
James Palis
James T MacGregor
Litron Laboratories (United States) · USUniversity of Rochester Medical Center · USDermatology Consulting Services · US

Funding

Versatile Mutation Assay Based on the Pig-A LocusR44ES015940 · NIEHS · LITRON LABORATORIES, LTD. · PI DERTINGER, STEPHEN D · 2008 to 2009
$768k
NIEHS NIH HHS R44 ES015940NIEHS NIH HHS R44ES015940
6 · The paper itself

Abstract

Two endpoints of genetic toxicity, mutation at the X-linked Pig-a gene and chromosomal damage in the form of micronucleated reticulocytes (MN-RETs), were evaluated in blood samples obtained from 28-day repeat-dosing studies typical of those employed in toxicity evaluations. Male Wistar Han rats were treated at 24-h intervals on days 1 through 28 with one of five prototypical genotoxicants: N-ethyl-N-nitrosourea, 7,12-dimethyl-12-benz[a]anthracene, 4-nitroquinoline-1-oxide (4NQO), benzo(a)pyrene, and N-methyl-N-nitrosourea. Flow cytometric scoring of CD59-negative erythrocytes (indicative of glycosylphosphatidylinositol anchor deficiency and hence Pig-a mutation) was performed using blood specimens obtained on days -1, 15, 29, and 56. Blood specimens collected on days 4 and 29 were evaluated for MN-RET frequency using flow cytometry-based MicroFlow Kits. With the exception of 4NQO, each chemical induced significant increases in the frequency of MN-RETs on days 4 and 29. All five agents increased the frequency of mutant phenotype (CD59 negative) reticulocytes (RETs) and erythrocytes. Mutation responses in RETs occurred earlier than in erythrocytes and tended to peak, or nearly peak, at day 29. In contrast, the mutant phenotype erythrocyte responses were modest on day 29 and required additional time to reach their maximal value. The observed kinetics were expected based on the known turnover of RETs and erythrocytes. The data show that RETs can serve as an appropriate indicator cell population for 28-day studies. Collectively, these data suggest that blood-based genotoxicity endpoints can be effectively incorporated into routine toxicology studies, a strategy that would reduce animal usage while providing valuable genetic toxicity information within the context of other toxicological endpoints.

Indexed as

AnimalsBacterial ToxinsCD59 AntigensChromosome AberrationsMaleMembrane ProteinsMicronuclei, Chromosome-DefectiveMutagensMutationPore Forming Cytotoxic ProteinsRatsRats, WistarReticulocytesToxicity TestsaerolysinBacterial ToxinsCD59 AntigensMembrane ProteinsMutagensphosphatidylinositol glycan-class A proteinPore Forming Cytotoxic Proteins

Identifiers

PMID20202993
PMCPMC2871757
OpenAlexW2146021438

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.